These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.
These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.
These guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the supportive care of myeloma patients and should be read in conjunction with the BCSH Guidelines for the diagnosis and management of myeloma.
This paper, written by an expert panel on behalf of the European Myeloma Network, reviews the available evidence and provides recommendations for the management of newly diagnosed myeloma patients.
This article, produced by the International Myeloma Working Group, reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of transplantation-eligible myeloma patients.
This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.
This paper provides updated guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas and incorporates further available information on diagnosis, prognosis and management and a new section on the management of multiple solitary plasmacytomas.